Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research
Not intended for US and UK audiences
BI 765423 has been developed to target IL-11, a key driver of fibrosis
New study will investigate potential of BI 765423 to improve lung function for pat......